TAOX
TAO Synergies Inc.5.54
+0.13+2.4%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
39.49MP/E (TTM)
-Basic EPS (TTM)
-14.20Dividend Yield
0%Recent Filings
8-K
Stockholders approve equity plan boost
TAO Synergies stockholders approved amending the 2020 Equity Incentive Plan at the December 18, 2025 annual meeting, boosting shares reserved by 500,000 to 3,175,000. They elected Bruce T. Bernstein as director until 2028 and authorized common stock issuance for prior convertible preferred stock and warrants to meet Nasdaq rules. Equity pool expanded. Low turnout signals dilution risk.
10-Q
Q3 FY2025 results
TAO Synergies kicked off TAO staking revenue at $203K in Q3 ended September 30, 2025—up from zero y/y—while operating loss narrowed to $1.8M from $2.0M (derived). Yet net loss widened to $3.9M from $5.7M, driven by $2.4M unrealized loss on digital assets versus prior Series C losses. Cash fell to $1.4M after $17.6M TAO buys, offset by $4.9M Series D proceeds and $2.0M warrant exercises; digital assets hit $15.4M. No debt, but Series D preferred carries $1.2M liquidation preference. Crypto markets stay volatile.
8-K
TAO Synergies raises $11M
TAO Synergies Inc. entered a $11 million private placement on October 13, 2025, selling 11,000 shares of Series E convertible preferred stock—initially convertible into 1,375,000 common shares at $8.00—and warrants for another 1,375,000 shares, closing October 15 for general corporate purposes and working capital. Backed by existing investors, advisor James Altucher, and new backer DCG, the deal bolsters the firm's TAO token treasury strategy amid Bittensor's DeAI push. Yet dilution looms without stockholder approval by December 31.
8-K
Board shakeup, Jacks advisory hire
TAO Synergies bolstered its board and digital asset strategy amid key changes. On August 28, 2025, directors Jonathan Schechter and Dr. Alan Tuchman resigned voluntarily, with Tuchman staying on as Chief Medical Officer; Robert Ephron, ex-Viacom ad exec, joined the board the next day, waiving initial options. The company engaged Bittensor expert Joseph Jacks as advisor on August 26, issuing him warrants for 100,000 shares at $8.40, expiring in five years, to enhance its TAO-focused treasury beyond staking. This positions TAO Synergies to actively contribute to the DeAI ecosystem. Forward-looking plans carry risks from market uncertainties.
10-Q
Q2 FY2025 results
TAO Synergies kicked off Q2 FY2025 with its first revenue from staking TAO tokens, a modest $3,962, while operating expenses climbed 92% year-over-year to $3.0M, driven by $2.2M in general and administrative costs including $700K warrant issuance fees and $969K in stock compensation. The operating loss widened to $3.0M from $1.6M last year, but net loss ballooned to $17.5M due to a $14.5M fair-value hit on warrant liabilities—far exceeding the $3.0M operating shortfall, mainly from derivative changes and crypto unrealized losses. Cash dipped to $14.4M after $4.5M invested in TAO holdings now valued at $4.5M, offset by $4.9M from Series D preferred stock; free cash flow isn't disclosed in the 10-Q. No debt, but Series D redemption looms starting September 2025. Crypto market volatility remains the key risk, with TAO's price swings threatening treasury value.
IPO
Website
Employees
Sector
Industry
BNAI
Brand Engagement Network Inc.
1.73-0.38
CGNT
Cognyte Software Ltd.
9.48-0.03
CXAI
CXApp Inc.
0.40+0.04
EBZT
Everything Blockchain, Inc.
0.20-0.01
ISTKF
INTELLISTAKE TECHNOLOGIES CORP.
1.36-0.03
SUPX
SuperX AI Technology Limited
16.57-1.43
TUYA
Tuya Inc.
2.19+0.02
UBXG
U-BX Technology Ltd.
1.95-0.12
VRSSF
VERSES AI INC.
2.20+0.02
YQAI
YOUNEEQAI TECHNICAL SVCS INC
0.52+0.00